BACKGROUND: The H30 subclone within Escherichia coli sequence type 131 (ST131-H30) has emerged rapidly to become the leading antibiotic-resistant E. coli strain. Hypervirulence, multidrug resistance, and opportunism have been proposed as explanations for its epidemic success. METHODS: We assessed 1133 consecutive unique E. coli clinical isolates from 5 medical centers (2010-2011) for H30 genotype, which we compared with epidemiological and clinical data extracted from medical records by blinded reviewers. Using univariable and multivariable logistic regression analysis, we explored associations of H30 with underlying host characteristics, clinical presentations, management, and outcomes, adjusting for host characteristics. RESULTS: The H30 (n = 107) isolates were associated with hosts who were older, male, locally and systemically compromised, and healthcare and antibiotic exposed. With multivariable adjustment for host factors, H30 lost its numerous significant univariable associations with initial clinical presentation, but remained strongly associated with clinical persistence (odds ratio [OR], 3.47; 95% confidence interval [CI], 1.89-6.37), microbiological persistence (OR, 4.46; 95% CI, 2.38-8.38), subsequent hospital admission (OR, 2.68; 95% CI, 1.35-5.33), and subsequent new infection (OR, 1.73; 95% CI, 1.01-3.00). These host-adjusted associations remained strong even with added adjustment for resistance to the initially prescribed antibiotics, and the adverse outcome associations (subsequent hospital admission, new infection) were independent of clinical and microbiological persistence. CONCLUSIONS: In addition to targeting compromised hosts and resisting multiple antibiotics, H30 isolates may have an intrinsic ability to cause highly persistent infections and later adverse outcomes. The basis for these host- and resistance-independent associations is unclear, but they should be considered when managing patients with H30 infections. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: The H30 subclone within Escherichia coli sequence type 131 (ST131-H30) has emerged rapidly to become the leading antibiotic-resistant E. coli strain. Hypervirulence, multidrug resistance, and opportunism have been proposed as explanations for its epidemic success. METHODS: We assessed 1133 consecutive unique E. coli clinical isolates from 5 medical centers (2010-2011) for H30 genotype, which we compared with epidemiological and clinical data extracted from medical records by blinded reviewers. Using univariable and multivariable logistic regression analysis, we explored associations of H30 with underlying host characteristics, clinical presentations, management, and outcomes, adjusting for host characteristics. RESULTS: The H30 (n = 107) isolates were associated with hosts who were older, male, locally and systemically compromised, and healthcare and antibiotic exposed. With multivariable adjustment for host factors, H30 lost its numerous significant univariable associations with initial clinical presentation, but remained strongly associated with clinical persistence (odds ratio [OR], 3.47; 95% confidence interval [CI], 1.89-6.37), microbiological persistence (OR, 4.46; 95% CI, 2.38-8.38), subsequent hospital admission (OR, 2.68; 95% CI, 1.35-5.33), and subsequent new infection (OR, 1.73; 95% CI, 1.01-3.00). These host-adjusted associations remained strong even with added adjustment for resistance to the initially prescribed antibiotics, and the adverse outcome associations (subsequent hospital admission, new infection) were independent of clinical and microbiological persistence. CONCLUSIONS: In addition to targeting compromised hosts and resisting multiple antibiotics, H30 isolates may have an intrinsic ability to cause highly persistent infections and later adverse outcomes. The basis for these host- and resistance-independent associations is unclear, but they should be considered when managing patients with H30 infections. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Lorena López-Cerero; María Dolores Navarro; Mar Bellido; Almudena Martín-Peña; Laura Viñas; José Miguel Cisneros; Sara Louise Gómez-Langley; Herminia Sánchez-Monteseirín; Isabel Morales; Alvaro Pascual; Jesús Rodríguez-Baño Journal: J Antimicrob Chemother Date: 2013-10-11 Impact factor: 5.790
Authors: James R Johnson; Brian Johnston; Michael A Kuskowski; Evgeni V Sokurenko; Veronika Tchesnokova Journal: Antimicrob Agents Chemother Date: 2015-05-18 Impact factor: 5.191
Authors: James R Johnson; Stephen Porter; Brian Johnston; Michael A Kuskowski; Rachel R Spurbeck; Harry L T Mobley; Deborah A Williamson Journal: Open Forum Infect Dis Date: 2015-06-06 Impact factor: 3.835
Authors: Ritu Banerjee; Brian Johnston; Christine Lohse; Stephen B Porter; Connie Clabots; James R Johnson Journal: Infect Control Hosp Epidemiol Date: 2013-02-13 Impact factor: 3.254
Authors: Veronika Tchesnokova; Mariya Billig; Sujay Chattopadhyay; Elena Linardopoulou; Pavel Aprikian; Pacita L Roberts; Veronika Skrivankova; Brian Johnston; Alena Gileva; Irina Igusheva; Angus Toland; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Brad T Cookson; Ferric C Fang; Barbara Kahl; Lance B Price; Scott J Weissman; Ajit Limaye; Delia Scholes; James R Johnson; Evgeni V Sokurenko Journal: J Clin Microbiol Date: 2013-07-10 Impact factor: 5.948
Authors: Nicola K Petty; Nouri L Ben Zakour; Mitchell Stanton-Cook; Elizabeth Skippington; Makrina Totsika; Brian M Forde; Minh-Duy Phan; Danilo Gomes Moriel; Kate M Peters; Mark Davies; Benjamin A Rogers; Gordon Dougan; Jesús Rodriguez-Baño; Alvaro Pascual; Johann D D Pitout; Mathew Upton; David L Paterson; Timothy R Walsh; Mark A Schembri; Scott A Beatson Journal: Proc Natl Acad Sci U S A Date: 2014-03-31 Impact factor: 11.205
Authors: Muhanad Mohamed; Connie Clabots; Stephen B Porter; Tricia Bender; Paul Thuras; James R Johnson Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Hajime Kanamori; Christian M Parobek; Jonathan J Juliano; James R Johnson; Brian D Johnston; Timothy J Johnson; David J Weber; William A Rutala; Deverick J Anderson Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Sibani Das; Amanda L Adler; Arianna Miles-Jay; Matthew P Kronman; Xuan Qin; Scott J Weissman; C A Burnham; Alexis Elward; Jason G Newland; Rangaraj Selvarangan; Kaede V Sullivan; Theoklis Zaoutis; Danielle M Zerr Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Shehara M Mendis; Shawn Vasoo; Brian D Johnston; Stephen B Porter; Scott A Cunningham; Sanjay R Menon; Christine B Teng; Partha P De; Robin Patel; James R Johnson; Ritu Banerjee Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191